nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—PTGS1—Ifosfamide—germ cell cancer	0.106	0.193	CbGbCtD
Thalidomide—CYP3A5—Ifosfamide—germ cell cancer	0.0638	0.116	CbGbCtD
Thalidomide—PTGS2—Cisplatin—germ cell cancer	0.0612	0.111	CbGbCtD
Thalidomide—PTGS2—Etoposide—germ cell cancer	0.0601	0.109	CbGbCtD
Thalidomide—CYP2C19—Ifosfamide—germ cell cancer	0.0515	0.0936	CbGbCtD
Thalidomide—PTGS1—Etoposide—germ cell cancer	0.0508	0.0924	CbGbCtD
Thalidomide—CYP2C9—Ifosfamide—germ cell cancer	0.0428	0.0778	CbGbCtD
Thalidomide—CYP2E1—Etoposide—germ cell cancer	0.0392	0.0714	CbGbCtD
Thalidomide—CYP3A5—Etoposide—germ cell cancer	0.0305	0.0555	CbGbCtD
Thalidomide—CYP1A2—Etoposide—germ cell cancer	0.0227	0.0413	CbGbCtD
Thalidomide—CYP2C9—Cisplatin—germ cell cancer	0.0208	0.0379	CbGbCtD
Thalidomide—CYP2C9—cardial valve—germ cell cancer	0.0082	0.0718	CbGeAlD
Thalidomide—FGFR2—skull—germ cell cancer	0.00665	0.0583	CbGeAlD
Thalidomide—FGFR2—skin epidermis—germ cell cancer	0.00411	0.036	CbGeAlD
Thalidomide—CYP2C19—urine—germ cell cancer	0.00228	0.02	CbGeAlD
Thalidomide—NFKB1—trigeminal ganglion—germ cell cancer	0.00226	0.0198	CbGeAlD
Thalidomide—FGFR2—neck—germ cell cancer	0.00197	0.0172	CbGeAlD
Thalidomide—NFKB1—eye—germ cell cancer	0.00195	0.0171	CbGeAlD
Thalidomide—CRBN—trigeminal ganglion—germ cell cancer	0.0019	0.0166	CbGeAlD
Thalidomide—CYP1A2—urine—germ cell cancer	0.00186	0.0163	CbGeAlD
Thalidomide—CRBN—embryo—germ cell cancer	0.00183	0.0161	CbGeAlD
Thalidomide—NFKB1—telencephalon—germ cell cancer	0.00178	0.0156	CbGeAlD
Thalidomide—CYP2C9—urine—germ cell cancer	0.00177	0.0155	CbGeAlD
Thalidomide—NFKB1—decidua—germ cell cancer	0.00168	0.0148	CbGeAlD
Thalidomide—CYP2E1—urine—germ cell cancer	0.00168	0.0147	CbGeAlD
Thalidomide—FGFR2—embryo—germ cell cancer	0.00164	0.0144	CbGeAlD
Thalidomide—CRBN—retina—germ cell cancer	0.00162	0.0142	CbGeAlD
Thalidomide—FGFR2—brainstem—germ cell cancer	0.0015	0.0132	CbGeAlD
Thalidomide—PTGS2—appendage—germ cell cancer	0.0015	0.0132	CbGeAlD
Thalidomide—CRBN—telencephalon—germ cell cancer	0.00149	0.0131	CbGeAlD
Thalidomide—CYP1A1—skin epidermis—germ cell cancer	0.00149	0.013	CbGeAlD
Thalidomide—NFKB1—gonad—germ cell cancer	0.00148	0.013	CbGeAlD
Thalidomide—NFKB1—uterus—germ cell cancer	0.00147	0.0129	CbGeAlD
Thalidomide—FGFR2—eye—germ cell cancer	0.00146	0.0128	CbGeAlD
Thalidomide—NFKB1—pituitary gland—germ cell cancer	0.00145	0.0127	CbGeAlD
Thalidomide—CRBN—decidua—germ cell cancer	0.00141	0.0124	CbGeAlD
Thalidomide—TNF—lymph node—germ cell cancer	0.00136	0.0119	CbGeAlD
Thalidomide—FGFR2—telencephalon—germ cell cancer	0.00134	0.0117	CbGeAlD
Thalidomide—NFKB1—adrenal gland—germ cell cancer	0.00129	0.0113	CbGeAlD
Thalidomide—FGFR2—skin of body—germ cell cancer	0.00127	0.0112	CbGeAlD
Thalidomide—NFKB1—bone marrow—germ cell cancer	0.00125	0.011	CbGeAlD
Thalidomide—PTGS2—skin epidermis—germ cell cancer	0.00125	0.0109	CbGeAlD
Thalidomide—CRBN—gonad—germ cell cancer	0.00124	0.0109	CbGeAlD
Thalidomide—CRBN—uterus—germ cell cancer	0.00124	0.0108	CbGeAlD
Thalidomide—CRBN—pituitary gland—germ cell cancer	0.00121	0.0106	CbGeAlD
Thalidomide—NFKB1—female gonad—germ cell cancer	0.00121	0.0106	CbGeAlD
Thalidomide—CRBN—medulla oblongata—germ cell cancer	0.00117	0.0103	CbGeAlD
Thalidomide—NFKB1—endocrine gland—germ cell cancer	0.00112	0.00982	CbGeAlD
Thalidomide—FGFR2—uterus—germ cell cancer	0.00111	0.0097	CbGeAlD
Thalidomide—NFKB1—head—germ cell cancer	0.00111	0.0097	CbGeAlD
Thalidomide—PTGS1—ganglion—germ cell cancer	0.0011	0.00964	CbGeAlD
Thalidomide—CRBN—adrenal gland—germ cell cancer	0.00108	0.0095	CbGeAlD
Thalidomide—CRBN—midbrain—germ cell cancer	0.00107	0.00937	CbGeAlD
Thalidomide—NFKB1—testis—germ cell cancer	0.00107	0.00937	CbGeAlD
Thalidomide—CRBN—bone marrow—germ cell cancer	0.00105	0.00919	CbGeAlD
Thalidomide—CRBN—spinal cord—germ cell cancer	0.00104	0.00915	CbGeAlD
Thalidomide—CRBN—female gonad—germ cell cancer	0.00101	0.00885	CbGeAlD
Thalidomide—NFKB1—cerebellum—germ cell cancer	0.000988	0.00865	CbGeAlD
Thalidomide—FGFR2—adrenal gland—germ cell cancer	0.000971	0.00851	CbGeAlD
Thalidomide—PTGS1—endothelium—germ cell cancer	0.000949	0.00831	CbGeAlD
Thalidomide—CRBN—endocrine gland—germ cell cancer	0.00094	0.00823	CbGeAlD
Thalidomide—FGFR2—spinal cord—germ cell cancer	0.000935	0.0082	CbGeAlD
Thalidomide—CRBN—head—germ cell cancer	0.000928	0.00813	CbGeAlD
Thalidomide—PTGS2—endothelium—germ cell cancer	0.000907	0.00795	CbGeAlD
Thalidomide—FGFR2—female gonad—germ cell cancer	0.000906	0.00793	CbGeAlD
Thalidomide—CRBN—testis—germ cell cancer	0.000896	0.00785	CbGeAlD
Thalidomide—PTGS1—blood vessel—germ cell cancer	0.000875	0.00767	CbGeAlD
Thalidomide—FGFR2—endocrine gland—germ cell cancer	0.000842	0.00738	CbGeAlD
Thalidomide—PTGS2—blood vessel—germ cell cancer	0.000836	0.00733	CbGeAlD
Thalidomide—FGFR2—head—germ cell cancer	0.000831	0.00728	CbGeAlD
Thalidomide—CRBN—cerebellum—germ cell cancer	0.000828	0.00725	CbGeAlD
Thalidomide—FGFR2—testis—germ cell cancer	0.000803	0.00704	CbGeAlD
Thalidomide—NFKB1—brain—germ cell cancer	0.000802	0.00703	CbGeAlD
Thalidomide—NFKB1—lymph node—germ cell cancer	0.000775	0.00679	CbGeAlD
Thalidomide—FGFR2—cerebellum—germ cell cancer	0.000742	0.0065	CbGeAlD
Thalidomide—CRBN—brain—germ cell cancer	0.000672	0.00589	CbGeAlD
Thalidomide—CRBN—lymph node—germ cell cancer	0.00065	0.00569	CbGeAlD
Thalidomide—FGFR2—brain—germ cell cancer	0.000602	0.00528	CbGeAlD
Thalidomide—PTGS2—trigeminal ganglion—germ cell cancer	0.000517	0.00453	CbGeAlD
Thalidomide—PTGS2—embryo—germ cell cancer	0.000499	0.00437	CbGeAlD
Thalidomide—CYP1A1—skin of body—germ cell cancer	0.000461	0.00404	CbGeAlD
Thalidomide—CYP2E1—telencephalon—germ cell cancer	0.000441	0.00386	CbGeAlD
Thalidomide—PTGS1—telencephalon—germ cell cancer	0.000424	0.00372	CbGeAlD
Thalidomide—PTGS2—telencephalon—germ cell cancer	0.000406	0.00355	CbGeAlD
Thalidomide—PTGS1—skin of body—germ cell cancer	0.000405	0.00355	CbGeAlD
Thalidomide—CYP1A1—uterus—germ cell cancer	0.000401	0.00351	CbGeAlD
Thalidomide—PTGS2—skin of body—germ cell cancer	0.000387	0.00339	CbGeAlD
Thalidomide—CYP2C19—endocrine gland—germ cell cancer	0.000378	0.00331	CbGeAlD
Thalidomide—PTGS1—uterus—germ cell cancer	0.000352	0.00308	CbGeAlD
Thalidomide—CYP2E1—medulla oblongata—germ cell cancer	0.000346	0.00303	CbGeAlD
Thalidomide—PTGS1—pituitary gland—germ cell cancer	0.000346	0.00303	CbGeAlD
Thalidomide—PTGS2—uterus—germ cell cancer	0.000336	0.00295	CbGeAlD
Thalidomide—PTGS2—pituitary gland—germ cell cancer	0.00033	0.00289	CbGeAlD
Thalidomide—CYP1A1—female gonad—germ cell cancer	0.000328	0.00287	CbGeAlD
Thalidomide—CYP2E1—adrenal gland—germ cell cancer	0.00032	0.00281	CbGeAlD
Thalidomide—CYP3A5—female gonad—germ cell cancer	0.00032	0.00281	CbGeAlD
Thalidomide—PTGS2—medulla oblongata—germ cell cancer	0.000319	0.00279	CbGeAlD
Thalidomide—CYP1A2—endocrine gland—germ cell cancer	0.000309	0.00271	CbGeAlD
Thalidomide—PTGS1—adrenal gland—germ cell cancer	0.000309	0.00271	CbGeAlD
Thalidomide—CYP2E1—spinal cord—germ cell cancer	0.000309	0.0027	CbGeAlD
Thalidomide—CYP1A1—endocrine gland—germ cell cancer	0.000305	0.00267	CbGeAlD
Thalidomide—CYP1A1—head—germ cell cancer	0.000301	0.00264	CbGeAlD
Thalidomide—CYP3A5—endocrine gland—germ cell cancer	0.000298	0.00261	CbGeAlD
Thalidomide—PTGS1—spinal cord—germ cell cancer	0.000297	0.00261	CbGeAlD
Thalidomide—PTGS2—adrenal gland—germ cell cancer	0.000295	0.00259	CbGeAlD
Thalidomide—CYP2C9—endocrine gland—germ cell cancer	0.000293	0.00257	CbGeAlD
Thalidomide—PTGS2—midbrain—germ cell cancer	0.000291	0.00255	CbGeAlD
Thalidomide—PTGS1—female gonad—germ cell cancer	0.000288	0.00252	CbGeAlD
Thalidomide—PTGS2—bone marrow—germ cell cancer	0.000285	0.0025	CbGeAlD
Thalidomide—PTGS2—spinal cord—germ cell cancer	0.000284	0.00249	CbGeAlD
Thalidomide—CYP2E1—endocrine gland—germ cell cancer	0.000278	0.00243	CbGeAlD
Thalidomide—PTGS2—female gonad—germ cell cancer	0.000275	0.00241	CbGeAlD
Thalidomide—CYP2E1—head—germ cell cancer	0.000274	0.0024	CbGeAlD
Thalidomide—PTGS1—endocrine gland—germ cell cancer	0.000268	0.00235	CbGeAlD
Thalidomide—CYP2E1—testis—germ cell cancer	0.000265	0.00232	CbGeAlD
Thalidomide—PTGS1—head—germ cell cancer	0.000264	0.00232	CbGeAlD
Thalidomide—PTGS2—endocrine gland—germ cell cancer	0.000256	0.00224	CbGeAlD
Thalidomide—PTGS1—testis—germ cell cancer	0.000255	0.00224	CbGeAlD
Thalidomide—PTGS2—head—germ cell cancer	0.000253	0.00221	CbGeAlD
Thalidomide—CYP2E1—cerebellum—germ cell cancer	0.000245	0.00214	CbGeAlD
Thalidomide—PTGS2—cerebellum—germ cell cancer	0.000225	0.00197	CbGeAlD
Thalidomide—Eye disorder—Etoposide—germ cell cancer	0.000223	0.000908	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—germ cell cancer	0.000223	0.000906	CcSEcCtD
Thalidomide—Cardiac disorder—Etoposide—germ cell cancer	0.000222	0.000902	CcSEcCtD
Thalidomide—Discomfort—Ifosfamide—germ cell cancer	0.000222	0.000901	CcSEcCtD
Thalidomide—Hypersensitivity—Vinblastine—germ cell cancer	0.000219	0.000892	CcSEcCtD
Thalidomide—Dermatitis exfoliative—Methotrexate—germ cell cancer	0.000219	0.000892	CcSEcCtD
Thalidomide—Decreased appetite—Bleomycin—germ cell cancer	0.000219	0.000889	CcSEcCtD
Thalidomide—Visual disturbance—Methotrexate—germ cell cancer	0.000218	0.000888	CcSEcCtD
Thalidomide—Muscle spasms—Cisplatin—germ cell cancer	0.000218	0.000888	CcSEcCtD
Thalidomide—CYP1A1—brain—germ cell cancer	0.000218	0.00191	CbGeAlD
Thalidomide—Angiopathy—Etoposide—germ cell cancer	0.000217	0.000882	CcSEcCtD
Thalidomide—Confusional state—Ifosfamide—germ cell cancer	0.000217	0.000882	CcSEcCtD
Thalidomide—Immune system disorder—Etoposide—germ cell cancer	0.000216	0.000878	CcSEcCtD
Thalidomide—Mediastinal disorder—Etoposide—germ cell cancer	0.000215	0.000876	CcSEcCtD
Thalidomide—Pain—Bleomycin—germ cell cancer	0.000215	0.000875	CcSEcCtD
Thalidomide—Oedema—Ifosfamide—germ cell cancer	0.000215	0.000874	CcSEcCtD
Thalidomide—Chills—Etoposide—germ cell cancer	0.000214	0.000872	CcSEcCtD
Thalidomide—Vision blurred—Cisplatin—germ cell cancer	0.000214	0.00087	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Dactinomycin—germ cell cancer	0.000214	0.000869	CcSEcCtD
Thalidomide—Asthenia—Vinblastine—germ cell cancer	0.000214	0.000869	CcSEcCtD
Thalidomide—Infection—Ifosfamide—germ cell cancer	0.000214	0.000869	CcSEcCtD
Thalidomide—Tremor—Cisplatin—germ cell cancer	0.000213	0.000865	CcSEcCtD
Thalidomide—Alopecia—Etoposide—germ cell cancer	0.000211	0.000859	CcSEcCtD
Thalidomide—Cerebrovascular accident—Methotrexate—germ cell cancer	0.000211	0.000859	CcSEcCtD
Thalidomide—Lethargy—Methotrexate—germ cell cancer	0.000211	0.000859	CcSEcCtD
Thalidomide—Nervous system disorder—Ifosfamide—germ cell cancer	0.000211	0.000857	CcSEcCtD
Thalidomide—CYP1A1—lymph node—germ cell cancer	0.000211	0.00185	CbGeAlD
Thalidomide—Ill-defined disorder—Cisplatin—germ cell cancer	0.000211	0.000857	CcSEcCtD
Thalidomide—TNF—SIDS Susceptibility Pathways—AVP—germ cell cancer	0.000211	0.00233	CbGpPWpGaD
Thalidomide—Thrombocytopenia—Ifosfamide—germ cell cancer	0.00021	0.000856	CcSEcCtD
Thalidomide—Anaemia—Cisplatin—germ cell cancer	0.00021	0.000854	CcSEcCtD
Thalidomide—NFKB1—Rac1/Pak1/p38/MMP-2 pathway—MYC—germ cell cancer	0.000209	0.00231	CbGpPWpGaD
Thalidomide—Skin disorder—Ifosfamide—germ cell cancer	0.000209	0.000849	CcSEcCtD
Thalidomide—Hyperhidrosis—Ifosfamide—germ cell cancer	0.000208	0.000845	CcSEcCtD
Thalidomide—TNF—Ceramide signaling pathway—MYC—germ cell cancer	0.000208	0.0023	CbGpPWpGaD
Thalidomide—Feeling abnormal—Bleomycin—germ cell cancer	0.000207	0.000843	CcSEcCtD
Thalidomide—FGFR2—Regulation of Actin Cytoskeleton—FGFR3—germ cell cancer	0.000207	0.00229	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—FGFR3—germ cell cancer	0.000207	0.00229	CbGpPWpGaD
Thalidomide—Osteoarthritis—Methotrexate—germ cell cancer	0.000207	0.000842	CcSEcCtD
Thalidomide—NFKB1—Regulation of Telomerase—MYC—germ cell cancer	0.000206	0.00228	CbGpPWpGaD
Thalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—TP53—germ cell cancer	0.000206	0.00228	CbGpPWpGaD
Thalidomide—Anorexia—Ifosfamide—germ cell cancer	0.000205	0.000833	CcSEcCtD
Thalidomide—Malaise—Cisplatin—germ cell cancer	0.000205	0.000833	CcSEcCtD
Thalidomide—Decreased appetite—Dactinomycin—germ cell cancer	0.000204	0.000829	CcSEcCtD
Thalidomide—Diarrhoea—Vinblastine—germ cell cancer	0.000204	0.000829	CcSEcCtD
Thalidomide—Dysgeusia—Etoposide—germ cell cancer	0.000204	0.000829	CcSEcCtD
Thalidomide—FGFR2—Signaling by ERBB4—FGFR3—germ cell cancer	0.000204	0.00225	CbGpPWpGaD
Thalidomide—Leukopenia—Cisplatin—germ cell cancer	0.000203	0.000827	CcSEcCtD
Thalidomide—Fatigue—Dactinomycin—germ cell cancer	0.000202	0.000823	CcSEcCtD
Thalidomide—NFKB1—Cellular responses to stress—H2AFZ—germ cell cancer	0.000202	0.00223	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—KLF4—germ cell cancer	0.000202	0.00223	CbGpPWpGaD
Thalidomide—Back pain—Etoposide—germ cell cancer	0.000201	0.000818	CcSEcCtD
Thalidomide—FGFR2—Signaling by NGF—FGF4—germ cell cancer	0.000201	0.00223	CbGpPWpGaD
Thalidomide—Hypotension—Ifosfamide—germ cell cancer	0.000201	0.000817	CcSEcCtD
Thalidomide—Pain—Dactinomycin—germ cell cancer	0.000201	0.000816	CcSEcCtD
Thalidomide—Muscle spasms—Etoposide—germ cell cancer	0.0002	0.000813	CcSEcCtD
Thalidomide—Urticaria—Bleomycin—germ cell cancer	0.0002	0.000813	CcSEcCtD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—germ cell cancer	0.000199	0.0022	CbGpPWpGaD
Thalidomide—CYP2E1—brain—germ cell cancer	0.000199	0.00174	CbGeAlD
Thalidomide—Body temperature increased—Bleomycin—germ cell cancer	0.000199	0.000809	CcSEcCtD
Thalidomide—FGFR2—Signaling by SCF-KIT—KIT—germ cell cancer	0.000199	0.0022	CbGpPWpGaD
Thalidomide—Dizziness—Vinblastine—germ cell cancer	0.000197	0.000801	CcSEcCtD
Thalidomide—Convulsion—Cisplatin—germ cell cancer	0.000197	0.0008	CcSEcCtD
Thalidomide—Mood swings—Methotrexate—germ cell cancer	0.000196	0.000797	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Ifosfamide—germ cell cancer	0.000196	0.000797	CcSEcCtD
Thalidomide—NFKB1—TGF-beta Receptor Signaling—HRAS—germ cell cancer	0.000195	0.00216	CbGpPWpGaD
Thalidomide—Ataxia—Methotrexate—germ cell cancer	0.000195	0.000791	CcSEcCtD
Thalidomide—FGFR2—Downstream signal transduction—FGFR3—germ cell cancer	0.000194	0.00215	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—FGFR3—germ cell cancer	0.000194	0.00214	CbGpPWpGaD
Thalidomide—Myalgia—Cisplatin—germ cell cancer	0.000193	0.000786	CcSEcCtD
Thalidomide—Feeling abnormal—Dactinomycin—germ cell cancer	0.000193	0.000786	CcSEcCtD
Thalidomide—Paraesthesia—Ifosfamide—germ cell cancer	0.000193	0.000785	CcSEcCtD
Thalidomide—Ill-defined disorder—Etoposide—germ cell cancer	0.000193	0.000785	CcSEcCtD
Thalidomide—Anxiety—Cisplatin—germ cell cancer	0.000193	0.000784	CcSEcCtD
Thalidomide—FGFR2—Signaling by ERBB2—FGFR3—germ cell cancer	0.000193	0.00213	CbGpPWpGaD
Thalidomide—Anaemia—Etoposide—germ cell cancer	0.000192	0.000782	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—germ cell cancer	0.000192	0.000781	CcSEcCtD
Thalidomide—Gastrointestinal pain—Dactinomycin—germ cell cancer	0.000192	0.00078	CcSEcCtD
Thalidomide—FGFR2—DAP12 signaling—FGFR3—germ cell cancer	0.000192	0.00212	CbGpPWpGaD
Thalidomide—Dyspnoea—Ifosfamide—germ cell cancer	0.000192	0.000779	CcSEcCtD
Thalidomide—PTGS1—brain—germ cell cancer	0.000192	0.00168	CbGeAlD
Thalidomide—Somnolence—Ifosfamide—germ cell cancer	0.000191	0.000777	CcSEcCtD
Thalidomide—Liver function test abnormal—Methotrexate—germ cell cancer	0.000191	0.000777	CcSEcCtD
Thalidomide—Discomfort—Cisplatin—germ cell cancer	0.000191	0.000777	CcSEcCtD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—FGFR3—germ cell cancer	0.00019	0.0021	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—KIT—germ cell cancer	0.00019	0.0021	CbGpPWpGaD
Thalidomide—Vomiting—Vinblastine—germ cell cancer	0.000189	0.00077	CcSEcCtD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—germ cell cancer	0.000189	0.00209	CbGpPWpGaD
Thalidomide—Malaise—Etoposide—germ cell cancer	0.000188	0.000763	CcSEcCtD
Thalidomide—FGFR2—Signaling by ERBB4—KIT—germ cell cancer	0.000187	0.00207	CbGpPWpGaD
Thalidomide—Breast disorder—Methotrexate—germ cell cancer	0.000187	0.00076	CcSEcCtD
Thalidomide—Vertigo—Etoposide—germ cell cancer	0.000187	0.00076	CcSEcCtD
Thalidomide—Decreased appetite—Ifosfamide—germ cell cancer	0.000187	0.00076	CcSEcCtD
Thalidomide—NFKB1—Developmental Biology—SOX2—germ cell cancer	0.000187	0.00207	CbGpPWpGaD
Thalidomide—Headache—Vinblastine—germ cell cancer	0.000187	0.000759	CcSEcCtD
Thalidomide—Toxic epidermal necrolysis—Methotrexate—germ cell cancer	0.000186	0.000758	CcSEcCtD
Thalidomide—Leukopenia—Etoposide—germ cell cancer	0.000186	0.000757	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Ifosfamide—germ cell cancer	0.000186	0.000755	CcSEcCtD
Thalidomide—Body temperature increased—Dactinomycin—germ cell cancer	0.000185	0.000754	CcSEcCtD
Thalidomide—Abdominal pain—Dactinomycin—germ cell cancer	0.000185	0.000754	CcSEcCtD
Thalidomide—Fatigue—Ifosfamide—germ cell cancer	0.000185	0.000754	CcSEcCtD
Thalidomide—Oedema—Cisplatin—germ cell cancer	0.000185	0.000754	CcSEcCtD
Thalidomide—Hypersensitivity—Bleomycin—germ cell cancer	0.000185	0.000754	CcSEcCtD
Thalidomide—PTGS1—lymph node—germ cell cancer	0.000185	0.00162	CbGeAlD
Thalidomide—Infection—Cisplatin—germ cell cancer	0.000184	0.000749	CcSEcCtD
Thalidomide—Constipation—Ifosfamide—germ cell cancer	0.000184	0.000748	CcSEcCtD
Thalidomide—Pain—Ifosfamide—germ cell cancer	0.000184	0.000748	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—PVRL2—germ cell cancer	0.000184	0.00203	CbGpPWpGaD
Thalidomide—PTGS2—brain—germ cell cancer	0.000183	0.0016	CbGeAlD
Thalidomide—Loss of consciousness—Etoposide—germ cell cancer	0.000183	0.000744	CcSEcCtD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—KIT—germ cell cancer	0.000183	0.00202	CbGpPWpGaD
Thalidomide—Nervous system disorder—Cisplatin—germ cell cancer	0.000182	0.000739	CcSEcCtD
Thalidomide—Cough—Etoposide—germ cell cancer	0.000182	0.000738	CcSEcCtD
Thalidomide—Thrombocytopenia—Cisplatin—germ cell cancer	0.000181	0.000738	CcSEcCtD
Thalidomide—Tachycardia—Cisplatin—germ cell cancer	0.000181	0.000736	CcSEcCtD
Thalidomide—Asthenia—Bleomycin—germ cell cancer	0.00018	0.000734	CcSEcCtD
Thalidomide—FGFR2—DAP12 interactions—FGFR3—germ cell cancer	0.00018	0.002	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—FGFR3—germ cell cancer	0.00018	0.002	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—FGFR3—germ cell cancer	0.00018	0.002	CbGpPWpGaD
Thalidomide—Convulsion—Etoposide—germ cell cancer	0.00018	0.000733	CcSEcCtD
Thalidomide—Skin disorder—Cisplatin—germ cell cancer	0.00018	0.000732	CcSEcCtD
Thalidomide—Hypertension—Etoposide—germ cell cancer	0.00018	0.00073	CcSEcCtD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CRABP1—germ cell cancer	0.00018	0.00199	CbGpPWpGaD
Thalidomide—Hyperhidrosis—Cisplatin—germ cell cancer	0.000179	0.000729	CcSEcCtD
Thalidomide—FGFR2—Signaling by EGFR—FGFR3—germ cell cancer	0.000179	0.00198	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—KIT—germ cell cancer	0.000179	0.00198	CbGpPWpGaD
Thalidomide—Pruritus—Bleomycin—germ cell cancer	0.000178	0.000724	CcSEcCtD
Thalidomide—FGFR2—Signaling by FGFR—KIT—germ cell cancer	0.000178	0.00197	CbGpPWpGaD
Thalidomide—Feeling abnormal—Ifosfamide—germ cell cancer	0.000177	0.00072	CcSEcCtD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—FGFR3—germ cell cancer	0.000177	0.00196	CbGpPWpGaD
Thalidomide—Chest pain—Etoposide—germ cell cancer	0.000177	0.00072	CcSEcCtD
Thalidomide—Eosinophilia—Methotrexate—germ cell cancer	0.000177	0.00072	CcSEcCtD
Thalidomide—PTGS2—lymph node—germ cell cancer	0.000177	0.00155	CbGeAlD
Thalidomide—Nausea—Vinblastine—germ cell cancer	0.000177	0.000719	CcSEcCtD
Thalidomide—FGFR2—Signaling by ERBB2—KIT—germ cell cancer	0.000177	0.00196	CbGpPWpGaD
Thalidomide—NFKB1—Fc-epsilon receptor I signaling in mast cells—HRAS—germ cell cancer	0.000177	0.00196	CbGpPWpGaD
Thalidomide—Anorexia—Cisplatin—germ cell cancer	0.000177	0.000718	CcSEcCtD
Thalidomide—FGFR2—Signaling by PDGF—FGFR3—germ cell cancer	0.000176	0.00195	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—KIT—germ cell cancer	0.000176	0.00195	CbGpPWpGaD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—germ cell cancer	0.000176	0.000715	CcSEcCtD
Thalidomide—NFKB1—B Cell Activation—FGFR3—germ cell cancer	0.000176	0.00195	CbGpPWpGaD
Thalidomide—Gastrointestinal pain—Ifosfamide—germ cell cancer	0.000176	0.000715	CcSEcCtD
Thalidomide—NFKB1—Oncostatin M Signaling Pathway—TP53—germ cell cancer	0.000176	0.00195	CbGpPWpGaD
Thalidomide—Pancreatitis—Methotrexate—germ cell cancer	0.000175	0.000713	CcSEcCtD
Thalidomide—Discomfort—Etoposide—germ cell cancer	0.000175	0.000712	CcSEcCtD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—KIT—germ cell cancer	0.000174	0.00193	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—PVRL2—germ cell cancer	0.000174	0.00193	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—MYC—germ cell cancer	0.000174	0.00193	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—KITLG—germ cell cancer	0.000174	0.00193	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—TP53—germ cell cancer	0.000174	0.00192	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—KIT—germ cell cancer	0.000173	0.00192	CbGpPWpGaD
Thalidomide—Hypotension—Cisplatin—germ cell cancer	0.000173	0.000704	CcSEcCtD
Thalidomide—Hypersensitivity—Dactinomycin—germ cell cancer	0.000173	0.000703	CcSEcCtD
Thalidomide—NFKB1—Rac1/Pak1/p38/MMP-2 pathway—TP53—germ cell cancer	0.000171	0.0019	CbGpPWpGaD
Thalidomide—Confusional state—Etoposide—germ cell cancer	0.000171	0.000696	CcSEcCtD
Thalidomide—Urticaria—Ifosfamide—germ cell cancer	0.000171	0.000695	CcSEcCtD
Thalidomide—NFKB1—LPA receptor mediated events—HRAS—germ cell cancer	0.00017	0.00188	CbGpPWpGaD
Thalidomide—Body temperature increased—Ifosfamide—germ cell cancer	0.00017	0.000691	CcSEcCtD
Thalidomide—Abdominal pain—Ifosfamide—germ cell cancer	0.00017	0.000691	CcSEcCtD
Thalidomide—Pancytopenia—Methotrexate—germ cell cancer	0.00017	0.000691	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Cisplatin—germ cell cancer	0.000169	0.000687	CcSEcCtD
Thalidomide—TNF—Aryl Hydrocarbon Receptor—HRAS—germ cell cancer	0.000169	0.00187	CbGpPWpGaD
Thalidomide—Infection—Etoposide—germ cell cancer	0.000169	0.000686	CcSEcCtD
Thalidomide—Asthenia—Dactinomycin—germ cell cancer	0.000168	0.000685	CcSEcCtD
Thalidomide—NFKB1—Oncostatin M Signaling Pathway—HRAS—germ cell cancer	0.000168	0.00186	CbGpPWpGaD
Thalidomide—Neutropenia—Methotrexate—germ cell cancer	0.000167	0.00068	CcSEcCtD
Thalidomide—FGFR2—B Cell Activation—FGFR3—germ cell cancer	0.000167	0.00185	CbGpPWpGaD
Thalidomide—Paraesthesia—Cisplatin—germ cell cancer	0.000166	0.000677	CcSEcCtD
Thalidomide—Thrombocytopenia—Etoposide—germ cell cancer	0.000166	0.000676	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Methotrexate—germ cell cancer	0.000166	0.000676	CcSEcCtD
Thalidomide—Tachycardia—Etoposide—germ cell cancer	0.000166	0.000674	CcSEcCtD
Thalidomide—FGFR2—Signaling by FGFR in disease—KIT—germ cell cancer	0.000166	0.00183	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—KIT—germ cell cancer	0.000166	0.00183	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—KIT—germ cell cancer	0.000166	0.00183	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—KITLG—germ cell cancer	0.000165	0.00183	CbGpPWpGaD
Thalidomide—Dyspnoea—Cisplatin—germ cell cancer	0.000165	0.000672	CcSEcCtD
Thalidomide—Skin disorder—Etoposide—germ cell cancer	0.000165	0.000671	CcSEcCtD
Thalidomide—Erectile dysfunction—Methotrexate—germ cell cancer	0.000165	0.00067	CcSEcCtD
Thalidomide—Hyperhidrosis—Etoposide—germ cell cancer	0.000164	0.000668	CcSEcCtD
Thalidomide—FGFR2—Signaling by EGFR—KIT—germ cell cancer	0.000164	0.00182	CbGpPWpGaD
Thalidomide—NFKB1—Rac1/Pak1/p38/MMP-2 pathway—HRAS—germ cell cancer	0.000164	0.00182	CbGpPWpGaD
Thalidomide—NFKB1—BCR signaling pathway—HRAS—germ cell cancer	0.000164	0.00182	CbGpPWpGaD
Thalidomide—Photosensitivity reaction—Methotrexate—germ cell cancer	0.000163	0.000664	CcSEcCtD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—KIT—germ cell cancer	0.000163	0.0018	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—KIT—germ cell cancer	0.000162	0.00179	CbGpPWpGaD
Thalidomide—Anorexia—Etoposide—germ cell cancer	0.000162	0.000658	CcSEcCtD
Thalidomide—NFKB1—B Cell Activation—KIT—germ cell cancer	0.000161	0.00179	CbGpPWpGaD
Thalidomide—Decreased appetite—Cisplatin—germ cell cancer	0.000161	0.000655	CcSEcCtD
Thalidomide—Diarrhoea—Dactinomycin—germ cell cancer	0.00016	0.000653	CcSEcCtD
Thalidomide—Pneumonia—Methotrexate—germ cell cancer	0.00016	0.000652	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Cisplatin—germ cell cancer	0.00016	0.000651	CcSEcCtD
Thalidomide—Vomiting—Bleomycin—germ cell cancer	0.00016	0.00065	CcSEcCtD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—FGFR3—germ cell cancer	0.00016	0.00177	CbGpPWpGaD
Thalidomide—Infestation NOS—Methotrexate—germ cell cancer	0.000159	0.000649	CcSEcCtD
Thalidomide—Infestation—Methotrexate—germ cell cancer	0.000159	0.000649	CcSEcCtD
Thalidomide—Drowsiness—Methotrexate—germ cell cancer	0.000159	0.000649	CcSEcCtD
Thalidomide—Depression—Methotrexate—germ cell cancer	0.000159	0.000647	CcSEcCtD
Thalidomide—Hypotension—Etoposide—germ cell cancer	0.000159	0.000645	CcSEcCtD
Thalidomide—Rash—Bleomycin—germ cell cancer	0.000159	0.000645	CcSEcCtD
Thalidomide—Pain—Cisplatin—germ cell cancer	0.000158	0.000645	CcSEcCtD
Thalidomide—Dermatitis—Bleomycin—germ cell cancer	0.000158	0.000644	CcSEcCtD
Thalidomide—Hypersensitivity—Ifosfamide—germ cell cancer	0.000158	0.000644	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Methotrexate—germ cell cancer	0.000158	0.000643	CcSEcCtD
Thalidomide—Renal failure—Methotrexate—germ cell cancer	0.000157	0.000637	CcSEcCtD
Thalidomide—Stomatitis—Methotrexate—germ cell cancer	0.000155	0.000632	CcSEcCtD
Thalidomide—NFKB1—B Cell Receptor Signaling Pathway—MYC—germ cell cancer	0.000155	0.00172	CbGpPWpGaD
Thalidomide—Conjunctivitis—Methotrexate—germ cell cancer	0.000155	0.00063	CcSEcCtD
Thalidomide—Asthenia—Ifosfamide—germ cell cancer	0.000154	0.000627	CcSEcCtD
Thalidomide—FGFR2—B Cell Activation—KIT—germ cell cancer	0.000153	0.0017	CbGpPWpGaD
Thalidomide—Sweating—Methotrexate—germ cell cancer	0.000153	0.000622	CcSEcCtD
Thalidomide—Feeling abnormal—Cisplatin—germ cell cancer	0.000153	0.000621	CcSEcCtD
Thalidomide—Paraesthesia—Etoposide—germ cell cancer	0.000152	0.00062	CcSEcCtD
Thalidomide—Pruritus—Ifosfamide—germ cell cancer	0.000152	0.000619	CcSEcCtD
Thalidomide—Haematuria—Methotrexate—germ cell cancer	0.000152	0.000618	CcSEcCtD
Thalidomide—Dyspnoea—Etoposide—germ cell cancer	0.000151	0.000616	CcSEcCtD
Thalidomide—Somnolence—Etoposide—germ cell cancer	0.000151	0.000614	CcSEcCtD
Thalidomide—NFKB1—Neural Crest Differentiation—MYC—germ cell cancer	0.00015	0.00166	CbGpPWpGaD
Thalidomide—Epistaxis—Methotrexate—germ cell cancer	0.00015	0.000612	CcSEcCtD
Thalidomide—NFKB1—Leptin signaling pathway—HRAS—germ cell cancer	0.00015	0.00166	CbGpPWpGaD
Thalidomide—Nausea—Bleomycin—germ cell cancer	0.000149	0.000608	CcSEcCtD
Thalidomide—PTGS2—C-MYB transcription factor network—KIT—germ cell cancer	0.000149	0.00165	CbGpPWpGaD
Thalidomide—Vomiting—Dactinomycin—germ cell cancer	0.000149	0.000607	CcSEcCtD
Thalidomide—Agranulocytosis—Methotrexate—germ cell cancer	0.000149	0.000605	CcSEcCtD
Thalidomide—TNF—TGF-beta Receptor Signaling—HRAS—germ cell cancer	0.000148	0.00164	CbGpPWpGaD
Thalidomide—Rash—Dactinomycin—germ cell cancer	0.000148	0.000602	CcSEcCtD
Thalidomide—Decreased appetite—Etoposide—germ cell cancer	0.000148	0.0006	CcSEcCtD
Thalidomide—Diarrhoea—Ifosfamide—germ cell cancer	0.000147	0.000598	CcSEcCtD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—KIT—germ cell cancer	0.000147	0.00162	CbGpPWpGaD
Thalidomide—Gastrointestinal disorder—Etoposide—germ cell cancer	0.000147	0.000596	CcSEcCtD
Thalidomide—Body temperature increased—Cisplatin—germ cell cancer	0.000146	0.000596	CcSEcCtD
Thalidomide—Fatigue—Etoposide—germ cell cancer	0.000146	0.000595	CcSEcCtD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—TP53—germ cell cancer	0.000146	0.00162	CbGpPWpGaD
Thalidomide—Pain—Etoposide—germ cell cancer	0.000145	0.00059	CcSEcCtD
Thalidomide—Constipation—Etoposide—germ cell cancer	0.000145	0.00059	CcSEcCtD
Thalidomide—Hepatitis—Methotrexate—germ cell cancer	0.000143	0.000582	CcSEcCtD
Thalidomide—NFKB1—Apoptosis—TP53—germ cell cancer	0.000143	0.00158	CbGpPWpGaD
Thalidomide—FGFR2—Neural Crest Differentiation—MYC—germ cell cancer	0.000143	0.00158	CbGpPWpGaD
Thalidomide—Dizziness—Ifosfamide—germ cell cancer	0.000142	0.000578	CcSEcCtD
Thalidomide—TNF—Developmental Biology—SOX2—germ cell cancer	0.000142	0.00157	CbGpPWpGaD
Thalidomide—Pharyngitis—Methotrexate—germ cell cancer	0.000142	0.000578	CcSEcCtD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—MYC—germ cell cancer	0.000141	0.00157	CbGpPWpGaD
Thalidomide—Urinary tract disorder—Methotrexate—germ cell cancer	0.000141	0.000575	CcSEcCtD
Thalidomide—Urethral disorder—Methotrexate—germ cell cancer	0.00014	0.000571	CcSEcCtD
Thalidomide—Feeling abnormal—Etoposide—germ cell cancer	0.00014	0.000569	CcSEcCtD
Thalidomide—Nausea—Dactinomycin—germ cell cancer	0.000139	0.000567	CcSEcCtD
Thalidomide—Gastrointestinal pain—Etoposide—germ cell cancer	0.000139	0.000565	CcSEcCtD
Thalidomide—FGFR2—Signaling Pathways in Glioblastoma—TP53—germ cell cancer	0.000138	0.00153	CbGpPWpGaD
Thalidomide—Visual impairment—Methotrexate—germ cell cancer	0.000138	0.000561	CcSEcCtD
Thalidomide—Vomiting—Ifosfamide—germ cell cancer	0.000137	0.000556	CcSEcCtD
Thalidomide—Hypersensitivity—Cisplatin—germ cell cancer	0.000137	0.000555	CcSEcCtD
Thalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—germ cell cancer	0.000136	0.0015	CbGpPWpGaD
Thalidomide—Rash—Ifosfamide—germ cell cancer	0.000136	0.000551	CcSEcCtD
Thalidomide—Dermatitis—Ifosfamide—germ cell cancer	0.000135	0.000551	CcSEcCtD
Thalidomide—Erythema multiforme—Methotrexate—germ cell cancer	0.000135	0.00055	CcSEcCtD
Thalidomide—Urticaria—Etoposide—germ cell cancer	0.000135	0.000549	CcSEcCtD
Thalidomide—NFKB1—Apoptosis Modulation and Signaling—TP53—germ cell cancer	0.000134	0.00149	CbGpPWpGaD
Thalidomide—Body temperature increased—Etoposide—germ cell cancer	0.000134	0.000546	CcSEcCtD
Thalidomide—Abdominal pain—Etoposide—germ cell cancer	0.000134	0.000546	CcSEcCtD
Thalidomide—Eye disorder—Methotrexate—germ cell cancer	0.000134	0.000544	CcSEcCtD
Thalidomide—Tinnitus—Methotrexate—germ cell cancer	0.000133	0.000543	CcSEcCtD
Thalidomide—Asthenia—Cisplatin—germ cell cancer	0.000133	0.000541	CcSEcCtD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—germ cell cancer	0.000133	0.00147	CbGpPWpGaD
Thalidomide—Cardiac disorder—Methotrexate—germ cell cancer	0.000133	0.00054	CcSEcCtD
Thalidomide—TNF—Apoptosis—MYC—germ cell cancer	0.000133	0.00147	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways in Glioblastoma—HRAS—germ cell cancer	0.000132	0.00147	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—TP53—germ cell cancer	0.000132	0.00146	CbGpPWpGaD
Thalidomide—Angiopathy—Methotrexate—germ cell cancer	0.00013	0.000528	CcSEcCtD
Thalidomide—NFKB1—TCR Signaling Pathway—HRAS—germ cell cancer	0.00013	0.00143	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—FGFR3—germ cell cancer	0.000129	0.00143	CbGpPWpGaD
Thalidomide—Immune system disorder—Methotrexate—germ cell cancer	0.000129	0.000526	CcSEcCtD
Thalidomide—Mediastinal disorder—Methotrexate—germ cell cancer	0.000129	0.000525	CcSEcCtD
Thalidomide—FGFR2—IRS-mediated signalling—HRAS—germ cell cancer	0.000129	0.00142	CbGpPWpGaD
Thalidomide—Chills—Methotrexate—germ cell cancer	0.000128	0.000522	CcSEcCtD
Thalidomide—Nausea—Ifosfamide—germ cell cancer	0.000128	0.000519	CcSEcCtD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—HRAS—germ cell cancer	0.000127	0.00141	CbGpPWpGaD
Thalidomide—Diarrhoea—Cisplatin—germ cell cancer	0.000127	0.000516	CcSEcCtD
Thalidomide—Alopecia—Methotrexate—germ cell cancer	0.000126	0.000514	CcSEcCtD
Thalidomide—TNF—Downstream signaling in naïve CD8+ T cells—HRAS—germ cell cancer	0.000126	0.0014	CbGpPWpGaD
Thalidomide—Mental disorder—Methotrexate—germ cell cancer	0.000125	0.00051	CcSEcCtD
Thalidomide—FGFR2—IRS-related events—HRAS—germ cell cancer	0.000125	0.00139	CbGpPWpGaD
Thalidomide—Hypersensitivity—Etoposide—germ cell cancer	0.000125	0.000509	CcSEcCtD
Thalidomide—Malnutrition—Methotrexate—germ cell cancer	0.000125	0.000507	CcSEcCtD
Thalidomide—FGFR2—IRS-related events triggered by IGF1R—HRAS—germ cell cancer	0.000124	0.00137	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—FGFR3—germ cell cancer	0.000123	0.00136	CbGpPWpGaD
Thalidomide—Dysgeusia—Methotrexate—germ cell cancer	0.000122	0.000496	CcSEcCtD
Thalidomide—NFKB1—B Cell Receptor Signaling Pathway—HRAS—germ cell cancer	0.000122	0.00135	CbGpPWpGaD
Thalidomide—Asthenia—Etoposide—germ cell cancer	0.000122	0.000495	CcSEcCtD
Thalidomide—NFKB1—Innate Immune System—FGF4—germ cell cancer	0.000121	0.00134	CbGpPWpGaD
Thalidomide—FGFR2—IGF1R signaling cascade—HRAS—germ cell cancer	0.000121	0.00134	CbGpPWpGaD
Thalidomide—FGFR2—Insulin receptor signalling cascade—HRAS—germ cell cancer	0.000121	0.00134	CbGpPWpGaD
Thalidomide—Back pain—Methotrexate—germ cell cancer	0.000121	0.00049	CcSEcCtD
Thalidomide—Pruritus—Etoposide—germ cell cancer	0.00012	0.000489	CcSEcCtD
Thalidomide—NFKB1—Signaling by NGF—KIT—germ cell cancer	0.000119	0.00132	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—MYC—germ cell cancer	0.000118	0.00131	CbGpPWpGaD
Thalidomide—Vomiting—Cisplatin—germ cell cancer	0.000118	0.000479	CcSEcCtD
Thalidomide—Vision blurred—Methotrexate—germ cell cancer	0.000117	0.000478	CcSEcCtD
Thalidomide—Rash—Cisplatin—germ cell cancer	0.000117	0.000475	CcSEcCtD
Thalidomide—Dermatitis—Cisplatin—germ cell cancer	0.000117	0.000475	CcSEcCtD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—TP53—germ cell cancer	0.000116	0.00129	CbGpPWpGaD
Thalidomide—Diarrhoea—Etoposide—germ cell cancer	0.000116	0.000472	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—FGF4—germ cell cancer	0.000116	0.00129	CbGpPWpGaD
Thalidomide—Ill-defined disorder—Methotrexate—germ cell cancer	0.000116	0.00047	CcSEcCtD
Thalidomide—Anaemia—Methotrexate—germ cell cancer	0.000115	0.000468	CcSEcCtD
Thalidomide—FGFR2—Innate Immune System—FGF4—germ cell cancer	0.000115	0.00127	CbGpPWpGaD
Thalidomide—TNF—Alzheimers Disease—TP53—germ cell cancer	0.000115	0.00127	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—KIT—germ cell cancer	0.000113	0.00125	CbGpPWpGaD
Thalidomide—Malaise—Methotrexate—germ cell cancer	0.000112	0.000457	CcSEcCtD
Thalidomide—Dizziness—Etoposide—germ cell cancer	0.000112	0.000457	CcSEcCtD
Thalidomide—NFKB1—Signaling by Interleukins—HRAS—germ cell cancer	0.000112	0.00124	CbGpPWpGaD
Thalidomide—Vertigo—Methotrexate—germ cell cancer	0.000112	0.000455	CcSEcCtD
Thalidomide—Leukopenia—Methotrexate—germ cell cancer	0.000112	0.000454	CcSEcCtD
Thalidomide—NFKB1—Immune System—PVRL2—germ cell cancer	0.000111	0.00123	CbGpPWpGaD
Thalidomide—FGFR2—Ectoderm Differentiation—MYC—germ cell cancer	0.000111	0.00123	CbGpPWpGaD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—HRAS—germ cell cancer	0.000111	0.00123	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—FGF4—germ cell cancer	0.00011	0.00122	CbGpPWpGaD
Thalidomide—Nausea—Cisplatin—germ cell cancer	0.00011	0.000448	CcSEcCtD
Thalidomide—TNF—Apoptosis—TP53—germ cell cancer	0.000109	0.00121	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—MYC—germ cell cancer	0.000109	0.00121	CbGpPWpGaD
Thalidomide—Cough—Methotrexate—germ cell cancer	0.000109	0.000442	CcSEcCtD
Thalidomide—Convulsion—Methotrexate—germ cell cancer	0.000108	0.000439	CcSEcCtD
Thalidomide—Vomiting—Etoposide—germ cell cancer	0.000108	0.000439	CcSEcCtD
Thalidomide—FGFR2—Disease—SLC2A3—germ cell cancer	0.000107	0.00119	CbGpPWpGaD
Thalidomide—Rash—Etoposide—germ cell cancer	0.000107	0.000435	CcSEcCtD
Thalidomide—Dermatitis—Etoposide—germ cell cancer	0.000107	0.000435	CcSEcCtD
Thalidomide—Headache—Etoposide—germ cell cancer	0.000106	0.000433	CcSEcCtD
Thalidomide—Myalgia—Methotrexate—germ cell cancer	0.000106	0.000431	CcSEcCtD
Thalidomide—Arthralgia—Methotrexate—germ cell cancer	0.000106	0.000431	CcSEcCtD
Thalidomide—Chest pain—Methotrexate—germ cell cancer	0.000106	0.000431	CcSEcCtD
Thalidomide—FGFR2—Immune System—PVRL2—germ cell cancer	0.000106	0.00117	CbGpPWpGaD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—germ cell cancer	0.000105	0.000428	CcSEcCtD
Thalidomide—Discomfort—Methotrexate—germ cell cancer	0.000105	0.000426	CcSEcCtD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—germ cell cancer	0.000104	0.00116	CbGpPWpGaD
Thalidomide—Confusional state—Methotrexate—germ cell cancer	0.000103	0.000417	CcSEcCtD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	0.000101	0.00112	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—MYC—germ cell cancer	0.000101	0.00112	CbGpPWpGaD
Thalidomide—Infection—Methotrexate—germ cell cancer	0.000101	0.000411	CcSEcCtD
Thalidomide—Nausea—Etoposide—germ cell cancer	0.000101	0.00041	CcSEcCtD
Thalidomide—FGFR2—Signaling by Insulin receptor—HRAS—germ cell cancer	0.0001	0.00111	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—MYC—germ cell cancer	0.0001	0.00111	CbGpPWpGaD
Thalidomide—Nervous system disorder—Methotrexate—germ cell cancer	9.97e-05	0.000406	CcSEcCtD
Thalidomide—Thrombocytopenia—Methotrexate—germ cell cancer	9.96e-05	0.000405	CcSEcCtD
Thalidomide—NFKB1—Innate Immune System—KITLG—germ cell cancer	9.93e-05	0.0011	CbGpPWpGaD
Thalidomide—Skin disorder—Methotrexate—germ cell cancer	9.88e-05	0.000402	CcSEcCtD
Thalidomide—Hyperhidrosis—Methotrexate—germ cell cancer	9.83e-05	0.0004	CcSEcCtD
Thalidomide—TNF—TNF alpha Signaling Pathway—HRAS—germ cell cancer	9.7e-05	0.00107	CbGpPWpGaD
Thalidomide—Anorexia—Methotrexate—germ cell cancer	9.69e-05	0.000394	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—KITLG—germ cell cancer	9.54e-05	0.00106	CbGpPWpGaD
Thalidomide—Hypotension—Methotrexate—germ cell cancer	9.5e-05	0.000386	CcSEcCtD
Thalidomide—FGFR2—Innate Immune System—KITLG—germ cell cancer	9.43e-05	0.00104	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—germ cell cancer	9.27e-05	0.00103	CbGpPWpGaD
Thalidomide—Musculoskeletal discomfort—Methotrexate—germ cell cancer	9.26e-05	0.000377	CcSEcCtD
Thalidomide—Insomnia—Methotrexate—germ cell cancer	9.2e-05	0.000374	CcSEcCtD
Thalidomide—Paraesthesia—Methotrexate—germ cell cancer	9.13e-05	0.000371	CcSEcCtD
Thalidomide—Dyspnoea—Methotrexate—germ cell cancer	9.07e-05	0.000369	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—KITLG—germ cell cancer	9.05e-05	0.001	CbGpPWpGaD
Thalidomide—Somnolence—Methotrexate—germ cell cancer	9.04e-05	0.000368	CcSEcCtD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—MYC—germ cell cancer	9.03e-05	0.001	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—TP53—germ cell cancer	8.95e-05	0.000991	CbGpPWpGaD
Thalidomide—Dyspepsia—Methotrexate—germ cell cancer	8.95e-05	0.000364	CcSEcCtD
Thalidomide—NFKB1—BDNF signaling pathway—HRAS—germ cell cancer	8.89e-05	0.000985	CbGpPWpGaD
Thalidomide—Decreased appetite—Methotrexate—germ cell cancer	8.84e-05	0.00036	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Methotrexate—germ cell cancer	8.78e-05	0.000357	CcSEcCtD
Thalidomide—Fatigue—Methotrexate—germ cell cancer	8.77e-05	0.000357	CcSEcCtD
Thalidomide—Pain—Methotrexate—germ cell cancer	8.7e-05	0.000354	CcSEcCtD
Thalidomide—FGFR2—Signaling by SCF-KIT—HRAS—germ cell cancer	8.58e-05	0.00095	CbGpPWpGaD
Thalidomide—Feeling abnormal—Methotrexate—germ cell cancer	8.38e-05	0.000341	CcSEcCtD
Thalidomide—Gastrointestinal pain—Methotrexate—germ cell cancer	8.31e-05	0.000338	CcSEcCtD
Thalidomide—TNF—Spinal Cord Injury—TP53—germ cell cancer	8.31e-05	0.00092	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—TP53—germ cell cancer	8.22e-05	0.00091	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—MYC—germ cell cancer	8.21e-05	0.000909	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—HRAS—germ cell cancer	8.21e-05	0.000909	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—HRAS—germ cell cancer	8.08e-05	0.000895	CbGpPWpGaD
Thalidomide—Urticaria—Methotrexate—germ cell cancer	8.08e-05	0.000329	CcSEcCtD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	8.06e-05	0.000892	CbGpPWpGaD
Thalidomide—Abdominal pain—Methotrexate—germ cell cancer	8.04e-05	0.000327	CcSEcCtD
Thalidomide—Body temperature increased—Methotrexate—germ cell cancer	8.04e-05	0.000327	CcSEcCtD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—HRAS—germ cell cancer	7.9e-05	0.000874	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—HRAS—germ cell cancer	7.72e-05	0.000854	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—HRAS—germ cell cancer	7.68e-05	0.00085	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—HRAS—germ cell cancer	7.64e-05	0.000846	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—MYC—germ cell cancer	7.63e-05	0.000844	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—HRAS—germ cell cancer	7.6e-05	0.000842	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—TP53—germ cell cancer	7.58e-05	0.000839	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—HRAS—germ cell cancer	7.54e-05	0.000835	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—germ cell cancer	7.52e-05	0.000833	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—HRAS—germ cell cancer	7.49e-05	0.00083	CbGpPWpGaD
Thalidomide—Hypersensitivity—Methotrexate—germ cell cancer	7.49e-05	0.000305	CcSEcCtD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TP53—germ cell cancer	7.42e-05	0.000821	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—FGFR3—germ cell cancer	7.38e-05	0.000817	CbGpPWpGaD
Thalidomide—Asthenia—Methotrexate—germ cell cancer	7.3e-05	0.000297	CcSEcCtD
Thalidomide—Pruritus—Methotrexate—germ cell cancer	7.19e-05	0.000293	CcSEcCtD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—HRAS—germ cell cancer	7.15e-05	0.000792	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—HRAS—germ cell cancer	7.15e-05	0.000792	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—HRAS—germ cell cancer	7.15e-05	0.000792	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	7.15e-05	0.000791	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—FGFR3—germ cell cancer	7.09e-05	0.000785	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—HRAS—germ cell cancer	7.09e-05	0.000785	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—FGF4—germ cell cancer	7.04e-05	0.00078	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—HRAS—germ cell cancer	7.03e-05	0.000778	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—FGFR3—germ cell cancer	7.01e-05	0.000776	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—HRAS—germ cell cancer	7e-05	0.000775	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—HRAS—germ cell cancer	6.98e-05	0.000772	CbGpPWpGaD
Thalidomide—Diarrhoea—Methotrexate—germ cell cancer	6.96e-05	0.000283	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—MYC—germ cell cancer	6.88e-05	0.000762	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—KIT—germ cell cancer	6.78e-05	0.00075	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—FGFR3—germ cell cancer	6.73e-05	0.000745	CbGpPWpGaD
Thalidomide—Dizziness—Methotrexate—germ cell cancer	6.72e-05	0.000274	CcSEcCtD
Thalidomide—FGFR2—Immune System—FGF4—germ cell cancer	6.68e-05	0.00074	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—germ cell cancer	6.68e-05	0.000739	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—HRAS—germ cell cancer	6.62e-05	0.000733	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—KIT—germ cell cancer	6.51e-05	0.000721	CbGpPWpGaD
Thalidomide—Vomiting—Methotrexate—germ cell cancer	6.46e-05	0.000263	CcSEcCtD
Thalidomide—PTGS2—C-MYB transcription factor network—HRAS—germ cell cancer	6.45e-05	0.000714	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—KIT—germ cell cancer	6.43e-05	0.000712	CbGpPWpGaD
Thalidomide—Rash—Methotrexate—germ cell cancer	6.41e-05	0.000261	CcSEcCtD
Thalidomide—Dermatitis—Methotrexate—germ cell cancer	6.41e-05	0.000261	CcSEcCtD
Thalidomide—Headache—Methotrexate—germ cell cancer	6.37e-05	0.000259	CcSEcCtD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—HRAS—germ cell cancer	6.34e-05	0.000701	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TP53—germ cell cancer	6.26e-05	0.000693	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—MYC—germ cell cancer	6.26e-05	0.000693	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—KIT—germ cell cancer	6.18e-05	0.000684	CbGpPWpGaD
Thalidomide—FGFR2—Disease—FGF4—germ cell cancer	6.17e-05	0.000683	CbGpPWpGaD
Thalidomide—Nausea—Methotrexate—germ cell cancer	6.04e-05	0.000246	CcSEcCtD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—germ cell cancer	5.91e-05	0.000654	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	5.85e-05	0.000648	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KITLG—germ cell cancer	5.79e-05	0.000641	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—TP53—germ cell cancer	5.73e-05	0.000634	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—germ cell cancer	5.65e-05	0.000626	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—SLC2A3—germ cell cancer	5.63e-05	0.000623	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—SLC22A3—germ cell cancer	5.54e-05	0.000614	CbGpPWpGaD
Thalidomide—FGFR2—Disease—H2AFZ—germ cell cancer	5.51e-05	0.00061	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KITLG—germ cell cancer	5.49e-05	0.000608	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—OXT—germ cell cancer	5.33e-05	0.000591	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SLC2A3—germ cell cancer	5.33e-05	0.000591	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	5.33e-05	0.000591	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HRAS—germ cell cancer	5.22e-05	0.000578	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TP53—germ cell cancer	5.14e-05	0.000569	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—HRAS—germ cell cancer	5.14e-05	0.000569	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KITLG—germ cell cancer	5.07e-05	0.000561	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—OXT—germ cell cancer	5.06e-05	0.00056	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—HRAS—germ cell cancer	4.87e-05	0.00054	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	4.56e-05	0.000505	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FGF4—germ cell cancer	4.55e-05	0.000504	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CRABP1—germ cell cancer	4.52e-05	0.0005	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—SLC2A3—germ cell cancer	4.47e-05	0.000495	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—SLC22A3—germ cell cancer	4.4e-05	0.000487	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FGF4—germ cell cancer	4.32e-05	0.000478	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—FGFR3—germ cell cancer	4.3e-05	0.000476	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—germ cell cancer	4.26e-05	0.000471	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—SLC2A3—germ cell cancer	4.21e-05	0.000466	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—SLC2A3—germ cell cancer	4.2e-05	0.000465	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—SLC22A3—germ cell cancer	4.14e-05	0.000459	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—SLC22A3—germ cell cancer	4.13e-05	0.000458	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—FGFR3—germ cell cancer	4.08e-05	0.000452	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—H2AFZ—germ cell cancer	4.07e-05	0.00045	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SLC2A3—germ cell cancer	3.97e-05	0.000439	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KIT—germ cell cancer	3.95e-05	0.000437	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SLC22A3—germ cell cancer	3.91e-05	0.000432	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—H2AFZ—germ cell cancer	3.86e-05	0.000427	CbGpPWpGaD
Thalidomide—FGFR2—Disease—FGFR3—germ cell cancer	3.77e-05	0.000417	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KIT—germ cell cancer	3.75e-05	0.000415	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KITLG—germ cell cancer	3.74e-05	0.000414	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AVP—germ cell cancer	3.66e-05	0.000405	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CRABP1—germ cell cancer	3.59e-05	0.000397	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KITLG—germ cell cancer	3.55e-05	0.000393	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—germ cell cancer	3.5e-05	0.000387	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AVP—germ cell cancer	3.47e-05	0.000384	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KIT—germ cell cancer	3.46e-05	0.000383	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CRABP1—germ cell cancer	3.38e-05	0.000374	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CRABP1—germ cell cancer	3.37e-05	0.000373	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—HRAS—germ cell cancer	3.32e-05	0.000367	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SLC2A3—germ cell cancer	3.24e-05	0.000359	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SLC22A3—germ cell cancer	3.2e-05	0.000354	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CRABP1—germ cell cancer	3.18e-05	0.000352	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGF4—germ cell cancer	3.06e-05	0.000339	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SLC2A3—germ cell cancer	2.96e-05	0.000328	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—HRAS—germ cell cancer	2.93e-05	0.000324	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SLC22A3—germ cell cancer	2.91e-05	0.000323	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HRAS—germ cell cancer	2.81e-05	0.000311	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FGFR3—germ cell cancer	2.78e-05	0.000308	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—HRAS—germ cell cancer	2.78e-05	0.000308	CbGpPWpGaD
Thalidomide—PTGS2—Disease—H2AFZ—germ cell cancer	2.74e-05	0.000303	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HRAS—germ cell cancer	2.67e-05	0.000295	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FGFR3—germ cell cancer	2.64e-05	0.000292	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CRABP1—germ cell cancer	2.61e-05	0.000288	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KIT—germ cell cancer	2.55e-05	0.000283	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC2A3—germ cell cancer	2.53e-05	0.00028	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—HRAS—germ cell cancer	2.53e-05	0.00028	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KITLG—germ cell cancer	2.52e-05	0.000279	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC22A3—germ cell cancer	2.49e-05	0.000276	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KIT—germ cell cancer	2.42e-05	0.000268	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CRABP1—germ cell cancer	2.38e-05	0.000263	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CRABP1—germ cell cancer	2.03e-05	0.000225	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MYC—germ cell cancer	1.9e-05	0.000211	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGFR3—germ cell cancer	1.87e-05	0.000207	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KIT—germ cell cancer	1.72e-05	0.00019	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HRAS—germ cell cancer	1.71e-05	0.000189	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HRAS—germ cell cancer	1.62e-05	0.000179	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HRAS—germ cell cancer	1.49e-05	0.000165	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MYC—germ cell cancer	1.4e-05	0.000155	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MYC—germ cell cancer	1.33e-05	0.000148	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—germ cell cancer	1.15e-05	0.000128	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRAS—germ cell cancer	1.1e-05	0.000122	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—germ cell cancer	1.09e-05	0.000121	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRAS—germ cell cancer	1.05e-05	0.000116	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MYC—germ cell cancer	9.45e-06	0.000105	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HRAS—germ cell cancer	7.42e-06	8.22e-05	CbGpPWpGaD
